V. Pilla Reddy

发表

Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response

A. Lau, T. Petreuș, E. Cadogan, 2021, Communications biology.

A Laboratory-Specific Scaling Factor to Predict the In Vivo Human Clearance of Aldehyde Oxidase Substrates

S. Neuhoff, V. Pilla Reddy, I. Gardner, 2020, Drug Metabolism and Disposition.

Model‐Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes

D. Boulton, Weifeng Tang, V. Pilla Reddy, 2021, CPT: pharmacometrics & systems pharmacology.

Preclinical Metabolism and Disposition of SB939 (Pracinostat), an Orally Active Histone Deacetylase Inhibitor, and Prediction of Human Pharmacokinetics

Haishan Wang, V. Pilla Reddy, K. Sangthongpitag, 2011, Drug Metabolism and Disposition.

Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy

M. Danhof, J. Proost, G. Groothuis, 2016, Pharmaceutical Research.

Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors

J. Ware, Diansong Zhou, V. Pilla Reddy, 2021, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics under the COVID‐19 storm

M. Jamei, Weifeng Tang, V. Pilla Reddy, 2020, British journal of clinical pharmacology.

Harnessing Clinical Trial and Real-World Data Towards an Understanding of Sex Effects on Drug Pharmacokinetics, Pharmacodynamics and Efficacy

V. Pilla Reddy, B. Williamson, R. Arends, 2022, Frontiers in Pharmacology.

Development of and insights from systems pharmacology models of antibody‐drug conjugates

V. Pilla Reddy, F. Mac Gabhann, Kathryn Ball, 2022, CPT: pharmacometrics & systems pharmacology.

Food constituent– and herb–drug interactions in oncology: Influence of quantitative modelling on Drug labelling

S. Neuhoff, V. Pilla Reddy, Jo Heeseung, 2021, British journal of clinical pharmacology.

Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug–drug interaction prediction

Anton Martinsson, V. Pilla Reddy, B. Williamson, 2022, CPT: pharmacometrics & systems pharmacology.

Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy

M. Danhof, J. Proost, G. Groothuis, 2016, Pharmaceutical Research.

Pharmacokinetic-Pharmacodynamic Modeling of the D2 and 5-HT2A Receptor Occupancy of Risperidone and Paliperidone in Rats

M. Danhof, J. Proost, G. Groothuis, 2012, Pharmaceutical Research.

Dopamine D2 Receptor Occupancy as a Predictor of Catalepsy in Rats: A Pharmacokinetic-Pharmacodynamic Modeling Approach

M. Danhof, J. Proost, G. Groothuis, 2014, Pharmaceutical Research.

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans

J. Dye, M. Pangalos, A. Herbert, 2022, Science Translational Medicine.

PBPK models for evaluating membrane transporter mediated DDIs: Current capabilities, case studies, future opportunities and recommendations.

Yuichi Sugiyama, Ming Zheng, Jan Snoeys, 2019, Clinical pharmacology and therapeutics.

Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P‐glycoprotein–cytochrome P450 3A4 dual substrates

S. Yamazaki, S. Neuhoff, V. Pilla Reddy, 2021, CPT: pharmacometrics & systems pharmacology.

ALT neuroblastoma chemoresistance due to telomere dysfunction–induced ATM activation is reversible with ATM inhibitor AZD0156

E. Cadogan, Aaron Smith, V. Pilla Reddy, 2021, Science Translational Medicine.

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations

Diansong Zhou, Venkatesh Pilla Reddy, Diansong Zhou, 2018, Clinical pharmacology and therapeutics.

Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label

Peter Ballard, Venkatesh Pilla Reddy, P. Ballard, 2018, CPT: pharmacometrics & systems pharmacology.

The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST

Rhys D O Jones, S. Guichard, W. Shao, 2020, Clinical Cancer Research.

Population Pharmacokinetic-Pharmacodynamic Modeling of Haloperidol in Patients With Schizophrenia Using Positive and Negative Syndrome Rating Scale

D. Rujescu, M. Danhof, J. Proost, 2013, Journal of clinical psychopharmacology.

Pharmacokinetic-Pharmacodynamic Modeling of the D2 and 5-HT2A Receptor Occupancy of Risperidone and Paliperidone in Rats

M. Danhof, J. Proost, G. Groothuis, 2012, Pharmaceutical Research.

Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of the Dopamine D2 Receptor Occupancy of Olanzapine in Rats

An Vermeulen, Meindert Danhof, Geny M. M. Groothuis, 2011, Pharmaceutical Research.

Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium

A. Smits, P. Annaert, V. Pilla Reddy, 2020, Clinical and translational science.

Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective

K. Venkatakrishnan, N. Hariparsad, J. Bolleddula, 2021, Clinical pharmacology and therapeutics.

Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection

M. Hughes, C. Fletcher, J. Currier, 2022, Clinical pharmacology and therapeutics.

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults

A. Aksyuk, J. Bouquet, M. Esser, 2023, The Journal of infectious diseases.

Evaluating the performance of machine‐learning regression models for pharmacokinetic drug–drug interactions

Anton Martinsson, V. Pilla Reddy, B. Williamson, 2022, CPT: pharmacometrics & systems pharmacology.

Pharmacokinetic–Pharmacodynamic Modeling of Severity Levels of Extrapyramidal Side Effects With Markov Elements

J. Proost, V. Pilla Reddy, L. Friberg, 2012, CPT: pharmacometrics & systems pharmacology.